Enjoy complimentary customisation on priority with our Enterprise License!
Report on How AI is Driving Market Transformation 
The RNA based therapeutics market size is forecast to increase by USD 1.27 billion at a CAGR of 5.54% between 2023 and 2028. The market is experiencing significant growth due to several key drivers. First, the increasing number of clinical studies focusing on messenger ribonucleic acid (mRNA) technology for cancer treatment is fueling market expansion. Additionally, the immunologic characteristics of RNA-based therapeutics, such as their ability to elicit both T-cell and B-cell responses, make them an attractive option for vaccine development against infectious diseases and genetic disorders. Furthermore, pharmacologic frontiers in RNA-based therapeutics are expanding, offering new opportunities for treating rare conditions. However, the high cost of developing RNA-based therapeutics remains a significant challenge for market growth. Despite this, the potential benefits of these innovative treatments continue to draw investment and collaboration from industry players.
RNA-based therapeutics represent a groundbreaking advancement in the healthcare industry, offering innovative solutions for various medical conditions. These therapeutics leverage the intricacies of RNA, a vital biological molecule, to manipulate gene expression, protein production, and immune responses. This market encompasses a wide range of applications, including oncology, infectious diseases, neurodegenerative disorders, and chronic illnesses. The increasing prevalence of chronic illnesses and the growing demand for personalized medicine are primary drivers propelling the RNA-based therapeutics market forward. The ability of RNA-based therapies to target specific genes and proteins, as well as their potential for treating rare conditions, makes them an attractive alternative to conventional treatments.
The regulatory requirements for RNA-based therapeutics are stringent, ensuring their safety and efficacy. These therapies undergo rigorous testing and clinical trials to secure approval from regulatory bodies. The regulatory landscape is continually evolving, with ongoing efforts to streamline the approval process and facilitate the development and commercialization of these innovative treatments. RNA-based therapeutics have a wide range of applications in healthcare, including cancer clinical studies, vaccine development, and gene delivery. In oncology, RNA interference and gene delivery techniques are being explored for their potential to target specific cancer-causing genes. In infectious diseases, RNA-based therapeutics can be used to silence viral genes or enhance immune responses.
Furthermore, for neurodegenerative disorders, RNA-based therapies hold promise in modifying protein expression and addressing the underlying causes of these conditions. Innovations in RNA-Based Therapeutics: Research and academic laboratories, hospitals, and diagnostic laboratories are at the forefront of innovation in RNA-based therapeutics. Small interfering RNAs (siRNAs) and microRNAs are among the most widely studied RNA-based therapeutics, with potential applications in various medical fields. Additionally, advancements in drug delivery systems and molecular diagnostics are enabling the development of more effective and targeted RNA-based therapies. RNA-based therapeutics represent a transformative force in the healthcare industry, offering innovative solutions for a diverse range of medical conditions.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The mRNA therapeutics segment is estimated to witness significant growth during the forecast period. MRNA therapeutics represent a groundbreaking method for treating various medical conditions by instructing cells to generate specific proteins. Notable applications include cancer immunotherapies, which encode tumor-related antigens via mRNA, stimulating the immune system to attack and eliminate cancer cells. Moderna Inc. (Moderna) is pioneering mRNA-based therapies for cancer, focusing on personalized cancer drugs/vaccines and additional oncology treatments. Moreover, mRNA therapeutics are being explored for diseases like heart conditions and rare genetic disorders. In gene replacement therapies, mRNA is introduced to generate proteins that are absent or defective due to genetic disorders, providing potential treatments for conditions such as cystic fibrosis and muscular dystrophy.
Furthermore, technological advancements continue to drive innovation in this field, with manufacturing plants being established for large-scale production and vaccine development underway. Biopharmaceutical drugs are increasingly incorporating mRNA technology to address disease targets, further expanding its application scope.
Get a glance at the market share of various segments Request Free Sample
The mRNA therapeutics segment accounted for USD 1.25 billion in 2018 and showed a gradual increase during the forecast period.
Europe is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The European market is witnessing notable expansion due to intensive research and development activities, substantial financial support from governments, and a well-established biopharmaceutical sector. Key contributors to this growth include Germany, the UK, and France. Notably, BioNTech SE, a German company, has spearheaded advancements in RNA technology, most notably with the development of mRNA vaccines during the COVID-19 crisis. This achievement has sparked increased investment in both academic and commercial RNA research across Europe. The European Union is a significant catalyst for the growth of the market, with initiatives like Horizon Europe, the EU's primary funding program for research and innovation, playing a pivotal role.
Furthermore, the EU's commitment to advancing scientific discovery and innovation is fueling the development of novel RNA-based treatments for various indications, including oncology pharmaceuticals, infectious diseases, and neurodegenerative disorders. The regulatory landscape for RNA-based therapeutics is complex, requiring stringent approval processes to ensure safety and efficacy. This market also holds potential for personalized medicine applications, further increasing its significance.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing investment and funding in RNA based therapeutics is the key driver of the market. Ribonucleic acid (RNA) based therapeutics are gaining significant attention in the scientific community due to their potential in addressing various chronic conditions. The global market for RNA based therapeutics is experiencing substantial growth, fueled by increasing investments from biopharmaceutical and biotechnological companies, as well as government bodies.
Furthermore, the funding supports the exploration of RNA's untapped potential in areas such as disease prevention in crops and cancer therapies. Molecular diagnostics, particularly in the field of keloids treatment, are another promising application. MicroRNAs, a type of RNA, have shown potential in diagnosing and treating various diseases. As research and academic laboratories continue to uncover new applications for RNA based therapeutics, the market is expected to expand further.
Increasing collaborations and partnerships is the upcoming trend in the market. Advancements in RNA-based therapies are being driven by an increasing number of collaborations and partnerships. These strategic alliances enable the combination of expertise, resources, and technologies to accelerate the development and availability of innovative treatments.
Furthermore, the collaboration focuses on utilizing advanced technologies to advance cancer treatment. These collaborations represent the pharmacologic frontiers of RNA-based therapeutics and their potential impact on clinical studies, particularly in the area of cancer treatment. Immunologic characteristics, such as T-cell and B-cell responses, are a significant focus of these therapeutic approaches, with vaccine types also under exploration. The therapeutic device market for RNA-based therapies is expected to grow substantially as these innovations continue to emerge.
The high cost of developing RNA based therapeutics is a key challenge affecting the market growth. RNA-based therapies, including RNA vaccines and RNA interference (RNAi) treatments, are making significant strides in the medical field, particularly in the arena of chronic illnesses. Regulating authorities, such as the Food and Drug Administration (FDA), have been closely monitoring the development of these innovative therapies. RNAi treatments inhibit gene expression, offering a potential solution for various genetic disorders and diseases. RNA vaccines, on the other hand, utilize RNA to trigger an immune response, showing great promise in preventing infectious diseases. Medical studies have shown promising results for RNA-based therapies, with RNA vaccines demonstrating high efficacy rates in clinical trials.
For instance, the Pfizer-BioNTech COVID-19 vaccine, based on RNA technology, has been instrumental in controlling the global pandemic. However, the high cost of developing RNA-based therapies poses a significant challenge in the market. Protein and antibody therapeutics, such as recombinant DNA technology-derived antibodies, have been a mainstay in the biopharmaceutical industry.
However, despite their success, RNA-based therapies have yet to reach the same level of market penetration due to their high development costs. In conclusion, RNA-based therapies, including RNA vaccines and RNAi treatments, are revolutionizing the medical field, offering potential solutions for various chronic illnesses and infectious diseases. Regulatory bodies are closely monitoring their development, and medical studies have shown promising results. However, the high cost of developing these therapies remains a significant challenge, hindering their widespread adoption and advancement in the market.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alnylam Pharmaceuticals Inc. - The company offers RNA Based Therapeutic such as Givlaari, Oxlumo, Leqvio, and Amvuttra.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
RNA-based therapies have emerged as a promising frontier in pharmacology, offering innovative solutions for various chronic conditions and complex diseases. These therapies, which include RNA interference (RNAi), RNA vaccines, and antisense technology, have shown significant potential in treating oncology, infectious diseases, neurodegenerative disorders, and rare conditions. RNAi technology, for instance, works by silencing specific genes, making it an attractive option for targeted therapy against cancer and genetic disorders. Regulatory requirements and molecular diagnostics play crucial roles in the development of RNA-based therapies. Biopharmaceutical and biotechnological companies, hospitals and diagnostic laboratories, research & academic laboratories, and government bodies are actively investing in RNA therapeutics classes, such as therapeutic ribozymes, small interfering RNAs (siRNAs), aptamers, and RNA vaccines.
Furthermore, advances in HTS, gene delivery, and manufacturing processes have facilitated the production of these therapies. RNA-based treatments for chronic diseases like heart disease, pulmonary diseases, and HIV have shown promising results in clinical studies, with some even demonstrating t-cell and b-cell responses. The innovative products in this field are expected to significantly impact healthcare spending by addressing the chronic disease burden. Technological advances continue to shape the RNA therapeutics landscape, with smart technology and enabling/enabled technologies playing a key role in vaccine development and personalized medicine applications. Public-private investments and collaborations are also driving the growth of this market. RNA-based therapies offer a unique approach to treating various diseases by manipulating protein expression and gene function. The immunologic characteristics of these therapies make them an attractive option for vaccine development and targeted therapy. With ongoing research and clinical studies, the potential applications of RNA-based therapies continue to expand, offering hope for patients suffering from a wide range of conditions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
208 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.54% |
|
Market growth 2024-2028 |
USD 1.27 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.12 |
|
Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
|
Performing market contribution |
Europe at 36% |
|
Key countries |
US, China, Germany, UK, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corp., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc., Ascidian Therapeutics Inc, AstraZeneca Plc, Beam Therapeutics Inc., Benitec Biopharma Inc., Biogen Inc., BioNTech SE, BioSpace, Circular Genomics Inc., CureVac AG, Esperovax, Gennova Biopharmaceuticals Ltd, Ionis Pharmaceuticals Inc., Moderna Inc., Novartis AG, Novo Nordisk AS, Omega Therapeutics Inc., Sarepta Therapeutics Inc., Silence Therapeutics plc, and Tevard Biosciences |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
With the growing adoption of AI across industries, Technavio has analyzed its impact on global RNA-based therapeutics market, centered on groundbreaking treatments like mRNA vaccines and RNA interference (RNAi) therapies, is advancing rapidly with the integration of Artificial Intelligence (AI). AI is driving innovation in drug discovery, personalized medicine, clinical trials, and patient monitoring. This analysis delves into AI's impact on the RNA-based therapeutics market, backed by data and real-world examples.
These insights, available exclusively through Technavio, provide an unparalleled significant impact of AI on the RNA-based therapeutics market, backed by real-world examples and data.
The report provides details of AI's impact on various segment
Learn more about how AI is transforming RNA-based Therapeutics Market - Buy Full Report Now
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
